Forest Devices Announces That FDA Has Designated the AlphaStroke Technology a Breakthrough Device
Pittsburgh, PA – May 21, 2021. Medical technology pioneer Forest Devices, Inc. (FDI), a medical device company focused on identifying patients with large vessel occlusive (LVO) strokes in the prehospital environment, today announced that the U.S. Food and Drug Administration (FDA) has designated its AlphaStroke technology as a Breakthrough Device.
“We are thrilled to work closely with the FDA to accelerate the introduction of what is currently the most needed intervention in for patients suffering a stroke,” said Matt Kesinger, CEO of FDI. “As a former EMT on ambulances, I experienced the challenge of correctly identifying stroke patients in the field. The AlphaStroke device is the only portable technology designed specifically to assist prehospital providers.”
The goal of the Breakthrough Device program is to provide patients and health care providers with timely access to certain medical devices that deliver more effective treatment of life-threatening or irreversibly debilitating diseases or conditions by speeding up their development, assessment, and review.
LVOs are the most debilitating type of stroke and require an interventional thrombectomy, only available at highly specialized hospitals. Every minute of treatment delay increases the risks of death and permanent disability.
About Forest Devices
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania and Calgary, Alberta that has developed AlphaStroke, the first prehospital stroke detection technology. The company strives to reduce functional disability from stroke by eliminating delays in stroke treatment.
Goose Capital, Inc. is an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs. Membership in Goose Capital is limited to executives who have founded or run major enterprises and who are willing to invest in and mentor early stage companies. Goose Capital primarily invests in early-stage companies with proprietary and disruptive technology, manageable capital needs, large addressable markets, the prospect for high margins and an exit strategy within a five-year time period. It typically invests in convertible debt and Series A preferred stock, although it reserves capital for follow-on investments in its portfolio companies.